IMPEL PHARMACEUTICALS INC: Nasdaq/NYSE listing notice — Impel Pharmaceuticals receives Nasdaq delisting notice for failure to meet MVLS/MVPHS minimums

IMPEL PHARMACEUTICALS INC

Nasdaq notified Impel on Oct 10, 2023, that it failed to regain compliance with $50M MVLS and $15M MVPHS requirements.
Trading suspension of common stock (IMPL) set for Oct 19, 2023, unless company requests hearing.
Impel intends to appeal the delisting determination and request a hearing before a Nasdaq Hearings Panel.
Appeal would automatically stay suspension pending the Panel's decision.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

IMPEL PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5450(b)(2)(A), 5450(b)(2)(C)

Exact text from the filing

April 11, 2023, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”) and the Company’s Market Value of Publicly-held Securities (“MVPHS”) was below the minimum $15 million required for continued listing on Nasdaq pursuant to Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Re

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-053547

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.